A brief look this week at
- Blood sugar and colorectal cancer risk
- Outcomes for people with defective mismatch repair on oxaliplatin
- Medicare’s preventive services
A brief look this week at
If you are diagnosed with stage III colon cancer, you will probably receive about six months of treatment with FOLFOX after surgery. Research shows that this treatment regimen helps prevent recurrence for some – but not all – patients with stage III colon cancer. A clinical trial has been launched to answer two questions about this current standard of care:
1. Will recurrence rates go down if both FOLFOX and celecoxib (a non-steroidal anti-inflammatory drug similar to aspirin) are used for treatment?
2. Will recurrence rates stay the same and long term side effects decrease if FOLFOX is used for three months?
Colorectal cancer patients getting oxaliplatin quickly learn to avoid cold. Drinks with ice, chilly air, even opening the freezer can produce sudden, sharp pain, burning, or an unpleasant pins and needle feeling in their throat and hands.
A small study has found that venlafaxine (Effexor) can completely eliminate acute neurotoxicity from oxaliplatin in about 1 out of 3 people. More than half of patients who took it had more than 50 percent relief from symptoms. Read the rest of this entry »
Colon cancers that are caused by defects in genes that repair damaged DNA don’t respond well to 5-FU treatment after surgery.
However, a new analysis of patients treated with FOLFOX (oxaliplatin, leucovorin, and 5-FU) found no differences between patients with deficient mismatch repair tumors and those with normal gene expression.
In this small study of 135 patients, the research team concluded that adding oxaliplatin to 5-FU and leucovorin may overcome resistance to chemotherapy in mismatch repair deficient and microsatellite instable (MSI) colon cancer. Read the rest of this entry »
XELOX, as second-line therapy, was found to be as effective as the more commonly used FOLFOX treatment for patients whose cancer had already gotten worse on treatment with Camptosar® (irinotecan).
XELOX combines an oral drug Xeloda® (capecitabine) with Eloxatin® (oxaliplatin). FOLFOX uses an infusional schedule of 5FU and leucovorin.
Researchers randomly compared XELOX to FOLFOX4 to treat 627 patients with metastatic colorectal cancer. Patients had already received initial therapy with Camptosar and either had their cancer progress or were unable to tolerate the treatments. Although outcomes were similar for the two regimens, side effects differed.